Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction‐Associated Steatotic Liver Disease in Midlife: The CARDIA Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.124.037948 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Seong W Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Metabolic‐dysfunction associated steatotic liver disease (MASLD) is associated with prevalent cardiovascular disease. More favorable cardiovascular health (CVH) profiles are associated with a lower prevalence of MASLD in cross‐sectional studies. The relationship between long‐term CVH patterns and MASLD prevalence in midlife remains unknown. Methods and Results Participants (aged 18–30 years at baseline) of the CARDIA (Coronary Artery Risk Development in Young Adults) study who had individual CVH components measured at 7 examinations over 20 years and liver fat assessed by noncontrast computed tomography at year 25 follow‐up were included. CVH score was defined using published American Heart Association definitions. Group‐based trajectory modeling was used to identify CVH trajectories. MASLD was defined as liver attenuation of ≤51 Hounsfield units with at least 1 metabolic risk factor after excluding other causes of liver fat. Logistic regression was used to examine associations of CVH trajectory groups and MASLD prevalence. At baseline, 39% of 2529 participants had high and 5% had low CVH, respectively. MASLD prevalence at year 25 was 23% (n=587). Five distinct CVH trajectories were identified. Between the 2 groups that started at similar CVH scores, those whose CVH declined over time had a higher prevalence of MASLD at year 25 (7.0% in high‐stable versus 23.0% high‐decreasing; 24.4% in moderate‐stable versus 35.7% in moderate‐decreasing). Lower and decreasing trajectories were associated with higher year‐25 MASLD prevalence compared with the high‐stable trajectory.
Conclusions
Achieving and maintaining high CVH scores starting in young adulthood lowers the risk of prevalent MASLD in midlife.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Preventive Medicine Northwestern University Feinberg School of Medicine Chicago IL USA.
- Department of Medicine, Division of Digestive and Liver Diseases University of Texas Southwestern Medical Center Dallas TX USA.
ORCID-Profile: Seong W Park, Hongyan Ning, Mercedes R Carnethon, Lisa B VanWagner
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Park, S. W., Ning, H., Carnethon, M. R., & VanWagner, L. B. (2025). Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction‐Associated Steatotic Liver Disease in Midlife: The CARDIA Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037948
Vancouver
Park SW, Ning H, Carnethon MR, VanWagner LB. Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction‐Associated Steatotic Liver Disease in Midlife: The CARDIA Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.037948
BibTeX
@article{Park2025,
author = {Park, Seong W and Ning, Hongyan and Carnethon, Mercedes R and VanWagner, Lisa B},
title = {Cardiovascular Health Trajectories and Prevalent Metabolic Dysfunction‐Associated Steatotic Liver Disease in Midlife: The CARDIA Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.037948}
}
EUVIMED